Experts In The News

European Pharmaceutical Review

Considering current developments in Alzheimer’s drugs, a US expert has predicted that the industry should “be prepared for more complex biological therapies that require intravenous infusion and vigilant monitoring for side effects; more like cancer therapies,” according to Dr Jeffrey Cummings, Alzheimer’s clinician-scientist and research professor at the School of Integrated Health Sciences, University of Nevada, Las Vegas.

K.S.N.V. T.V. News 3

Las Vegas loves its sports teams. The WNBA’s Aces arrived from San Antonio, Texas. We welcomed the Raiders, and soon-to-be Las Vegas A’s from Oakland. But the Vegas Golden Knights are Vegas-born, and their birth certificate was forged in our community’s darkest hours.

Medical Xpress

The world of Alzheimer's treatments is at an inflection point as more potential drugs make their way out of clinical trials. On the heels of newly FDA-approved drugs Aduhelm (aducanumab) in 2021 and Leqembi (lecanemab) in 2023, a UNLV researcher says that 2024 is a "learning year" for Alzheimer's drug development.

Travel + Leisure

Picture this: It's about 20 minutes after takeoff, and you hear your captain make an announcement. "Ladies and gentlemen, we've reached our cruising altitude of 35,000 feet," they say. Or, maybe they say 36,000 feet, or 40,000 feet, or 33,000 feet. Cruising altitude isn't actually a fixed number — there are many factors that go into computing this for every flight.

K.V.V.U. T.V. Fox 5

UNLV research shows a decline from the pandemic surge of Californians moving to Nevada.

Las Vegas Review Journal

Las Vegas’ history is filled with infamous stories of mobsters leaving their mark on the city throughout the years, and of course, they also need places to live while in Sin City.

Newswise

The world of Alzheimer’s treatments is at an inflection point as more potential drugs make their way out of clinical trials. And on the heels of newly FDA-approved drugs Aduhelm® (aducanumab) in 2021 and Leqembi® (lecanemab) in 2023, a UNLV researcher says that 2024 is a “learning year” for Alzheimer’s drug development.

K.V.V.U. T.V. Fox 5

The UNLV Athletics program received a $1.05 million donation for its “Rebel Up” campaign. The donation is thanks to Diana Bennett. UNLV Athletics says Bennett served as the chair of the UNLV Foundation Board of Trustees from 2020-2022 and has been a board member since 2008. The donation will establish the creation of the Diana Bennett Career Development Program for Women’s Sports.